Treatment of Tardive Dystonia Induced by Antipsychotics, Old and New

Clinical Neuropharmacology

Volumn 38, Issue 4, 2015, Pages 121-126

  Gourzis, Philippos ^a   Skokou, Maria ^a   Soubasi, Evanthia ^a   Katrivanou, Aggeliki ^a   Polychronopoulos, Panagiotis ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

atypical antipsychotics; extrapyramidal side effects; quetiapine; tardive dystonia; treatment

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIOPROPERAZINE; THIORIDAZINE; TRIFLUOPERAZINE; VALPROIC ACID; ZIPRASIDONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DYSTONIA; FEMALE; HUMAN; MALE; MOOD DISORDER; PRIORITY JOURNAL; PSYCHOSIS; TARDIVE DYSTONIA; TREATMENT OUTCOME; COMPLICATION; MIDDLE AGED; MOVEMENT DISORDERS; RETROSPECTIVE STUDY; SLEEP WAKE DISORDERS;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; QUETIAPINE FUMARATE; RETROSPECTIVE STUDIES; SLEEP WAKE DISORDERS;

EID: 84938333847     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000086     Document Type: Article

References (62)

1. Bakker PR, de Groot IW, van Os J, Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS One 2011; 6: e25588.
2. Adityanjee, Aderibigbe YA, Jampala VC, The current status of tardive dystonia. Biol Psychiatry 1999; 45: 715-730.
3. van Harten PN, Kahn RS,. Tardive dystonia. Schizophr Bull 1999; 25: 741-748.
4. van Harten PN, Hoek HW, Kahn RS,. Fortnightly review-acute dystonia induced by drug treatment. BMJ 1999; 319: 623-626.
5. Caroff SN, Hurford I, Lybrand J, Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin 2011; 29: 127-148.
6. Kiriakakis V, Bhatia KP, Quinn NP, The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 1998; 121: 2053-2066.
7. Buscombe C, Alusi SH, Kahn DA,. A biopsychosocial approach to improving quality of life in tardive dystonia. J Psychiatr Pract 2010; 16: 350-357.
8. Lauterbach EC, Freeman A, Vogel RL,. Differential DSM-111 psychiatric disorder prevalence profiles in dystonia and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2004; 16: 29-36.
9. Chong SA, Tay JAM, Subramaniam M, Mortality rates among patients with schizophrenia and tardive dyskinesia. J Clin Psychopharmacol 2009; 29: 5-8.
10. Leucht S, Corves C, Arbter D, Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
11. Tenback DE, van Harten PN, Slooff CJ, Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. J Clin Psychiatry 2005; 66: 1130-1133.
12. Correll CU, Schenk EM,. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21: 151-156.
13. Jones PB, Barnes TRE, Davies L, Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia-Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-U1076.
14. Correll CU, Leucht S, Kane JM,. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414-425.
15. Arango C, Adami H, Sherr JD, Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. Am J Psychiatry 1999; 156: 1097-1099.
16. Emsley R, Niehaus DJH, Oosthuizen PP, Subjective awareness of tardive dyskinesia and insight in schizophrenia. Eur Psychiatry 2011; 26: 293-296.
17. Simpson GM,. The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatry 2000; 61: 39-44.
18. Van Harten PN, Kamphuis DJ, Matroos GE,. Use of clozapine in tardive dystonia. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 263-274.
19. Factor SA, Friedman JH,. The emerging role of clozapine in the treatment of improvement disorders. Mov Disord 1997; 12: 483-496.
20. Peritogiannis V, Tsouli S,. Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature. J Psychopharmacol 2010; 24: 1121-1125.
21. Cortese L, Caligiuri MP, Williams R, Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol 2008; 28: 69-73.
22. Emsley R, Turner HJ, Schronen J, A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 2004; 65: 696-701.
23. Navarro Pacheco BV, Montejo González AL, Martín Carrasco M,. Utility of quetiapine in tardive dyskinesia. Utilidad de la quetiapina en la discinesia tardía. Actas Esp Psiquiatr 2003; 31: 347-352.
24. Haddad PM, Dursun SM,. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008; 23: 15-26.
25. Llorca PM, Chereau I, Bayle FJ, Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 2002; 17: 129-138.
26. Kapur S, Zipursky RB, Remington G,. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156: 286-293.
27. Saller CF, Salama AI,. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993; 112: 285-292.
28. Fernandez HH, Friedman JH, Jacques C, Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999; 14: 484-487.
29. Fernandez HH, Friedman JH,. Classification and treatment of tardive syndromes. Neurologist 2003; 9: 16-27.
30. Burke RE,. Neuroleptic-induced tardive dyskinesia variants. In: Lang AE, Weiner WJ, eds. Drug-induced movement disorders. New York: Futura Publishing Company; 1992: 167-198.
31. Burke RE, Fahn S, Marsden CD, Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985; 35: 73-77.
32. Van Harten PN, Matroos GE, Hoek HW, The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia: the Curaçao extrapyramidal syndromes study: I. Schizophr Res 1996; 19: 195-203.
33. Weiden PJ,. Switching antipsychotics: an updated review with a focus on quetiapine. J Psychopharmacol 2006; 20: 104-118.
34. Lapaz AGA, Fernandez LG, Martinez MJ,. Quetiapine treatment of risperidone-related tardive dyskinesia. A case report. Actas Esp Psiquiatr 2003; 31: 306-306.
35. Gourzis P, Polychronopoulos P, Papapetropoulos S, Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics-a report of 2 cases. Clin Neuropharmacol 2005; 28: 195-196.
36. Gourzis P, Polychronopoulos P, Argyriou AA, Quetiapine successfully treating oculogyric crisis induced by antipsychotic drugs. J Clin Neurosci 2007; 14: 396-398.
37. Abbasian C, Power P,. A case of aripiprazole and tardive dyskinesia. J Psychopharmacol 2009; 23: 214-215.
38. Alptekin K, Kivircik BB,. Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia. Int Clin Psychopharmacol 2002; 17: 263-264.
39. Bressan RA, Jones HM, Pilowsky LS,. Atypical antipsychotic drugs and tardive dyskinesia: relevance of D 2 receptor affinity. J Psychopharmacol 2004; 18: 124-127.
40. Fernandez HH, Friedman JH,. The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs 1999; 11: 467-483.
41. Havaki-Kontaxaki BJ, Kontaxakis VP, Margariti MM, Treatment of severe neuroleptic-induced tardive torticollis. Ann Gen Hosp Psychiatry 2003; 2: 9.
42. van Harten PN, Hovestadt A,. Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord 2006; 21: 1276-1277.
43. Kang UJ, Burke RE, Fahn S,. Natural history and treatment of tardive dystonia. Mov Disord 1986; 1: 193-208.
44. Bressman SB,. Dystonia update. Clin Neuropharmacol 2000; 23: 239-251.
45. Katsakiori PF, Kefalopoulou Z, Markaki E, Deep brain stimulation for secondary dystonia: results in 8 patients. Acta Neurochir (Wien) 2009; 151: 473-478.
46. Klawans Jr HL, Rubovits R,. An experimental model of tardive dyskinesia. J Neural Transm 1972; 33: 235-246.
47. Tarsy D, Baldessarini RJ,. Pharmacologically induced behavioural supersensitivity to apomorphine. Nat New Biol 1973; 245: 262-263.
48. Casey DE,. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004; 65: 25-28.
49. Stahl SM,. "Hit-and-Run" actions at dopamine receptors, part 2: Illustrating fast dissociation from dopamine receptors that typifies atypical antipsychotics. J Clin Psychiatry 2001; 62: 747-748.
50. Kasper S, Tauscher J, Heiden A,. Quetiapine: efficacy and tolerability in schizophrenia. Eur Neuropsychopharmacol 2001; 11: S405-S413.
51. Seeman P, Tallerico T,. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999; 156: 876-884.
52. Kapur S, Remington G,. Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001; 50: 873-883.
53. Kapur S, Seeman P,. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001; 158: 360-369.
54. Nasrallah HA, Mulvihill T,. Iatrogenic disorders associated with conventional vs. atypical antipsychotics. Ann Clin Psychiatry 2001; 13: 215-227.
55. Stoklosa J, Öngr D,. Rational antipsychotic choice: weighing the risk of tardive dyskinesia and metabolic syndrome. Harv Rev Psychiatry 2011; 19: 271-276.
56. Morgenstern H, Glazer WM,. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993; 50: 723-733.
57. Kim J, MacMaster E, Schwartz TL,. Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations. Drugs Context 2014; 3: 212259.
58. Twaites BR, Wilton LV, Shakir SAW,. The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England. J Psychopharmacol 2007; 21: 392-399.
59. Divac N, Prostran M, Jakovcevski I, Second-generation antipsychotics and extrapyramidal adverse effects. BioMed Res Int 2014; 2014.
60. Casey DE,. Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr 2006; 11: 25-31.
61. Tarsy D, Baldessarini RJ,. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21: 589-598.
62. De Hert M, Peuskens B, van Winkel R, Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE®. Schizophr Res 2006; 88: 222-226.